LLYC Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 1/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Eli Lilly and Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$702.90 |
52 Week High | US$736.00 |
52 Week Low | US$338.00 |
Beta | 0.37 |
1 Month Change | -0.58% |
3 Month Change | 21.93% |
1 Year Change | 107.96% |
3 Year Change | 344.73% |
5 Year Change | n/a |
Change since IPO | 617.98% |
Recent News & Updates
Recent updates
Shareholder Returns
LLYC | AT Pharmaceuticals | AT Market | |
---|---|---|---|
7D | -0.9% | -1.3% | -0.3% |
1Y | 108.0% | 4.4% | 2.4% |
Return vs Industry: LLYC exceeded the Austrian Pharmaceuticals industry which returned 4.8% over the past year.
Return vs Market: LLYC exceeded the Austrian Market which returned 1.8% over the past year.
Price Volatility
LLYC volatility | |
---|---|
LLYC Average Weekly Movement | 4.2% |
Pharmaceuticals Industry Average Movement | 5.1% |
Market Average Movement | 3.4% |
10% most volatile stocks in AT Market | 5.4% |
10% least volatile stocks in AT Market | 1.6% |
Stable Share Price: LLYC has not had significant price volatility in the past 3 months.
Volatility Over Time: LLYC's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1876 | 43,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
LLYC fundamental statistics | |
---|---|
Market cap | €635.35b |
Earnings (TTM) | €4.92b |
Revenue (TTM) | €32.06b |
128.2x
P/E Ratio19.7x
P/S RatioIs LLYC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LLYC income statement (TTM) | |
---|---|
Revenue | US$34.12b |
Cost of Revenue | US$7.08b |
Gross Profit | US$27.04b |
Other Expenses | US$21.80b |
Earnings | US$5.24b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
Earnings per share (EPS) | 5.82 |
Gross Margin | 79.25% |
Net Profit Margin | 15.36% |
Debt/Equity Ratio | 233.4% |
How did LLYC perform over the long term?
See historical performance and comparison